ONCLIVE NEWS NETWORK: ON LOCATION WILL BE LIVE AT ESMO THIS WEEK - STAY TUNED FOR MORE INFORMATION!

Dr. Levy Discusses Recent Updates in Immunotherapy for Lung Cancer

Benjamin P. Levy, MD
Published: Monday, Nov 10, 2014

Benjamin P. Levy, MD, director, Thoracic Medical Oncology, Mount Sinai Beth Israel, associate director, Cancer Clinical Trials Office, Mount Sinai Hospital, Mt. Sinai School of Medicine, discusses new data on immunotherapy for lung cancer.

Levy says the field of immunotherapy in lung cancer is very exciting. The unique ability to harness a patients’ immune system to attack the cancer is what sets these agents apart from other agents. There are currently multiple immunotherapeutic agents being looked at for the treatment of lung cancer, Levy says.

Results of the CheckMate 063 study, which evaluated the efficacy of nivolumab, showed that nivolumab delivered durable responses in patients with advanced squamous cell lung cancer.

Levy says approximately 15% of patients treated with nivolumab in this study responded — historical response rates in this setting are approximately 5-10%. Nivolumab also demonstrated a one-year overall survival rate of 40% in this trial. Levy says this is unprecedented, as historical rates are approximately 10-15%.

More resources are needed to find biomarkers to determine which patients will respond to each immunotherapy.

<<< View more from the 2014 Annual Lung Cancer Symposium

Benjamin P. Levy, MD, director, Thoracic Medical Oncology, Mount Sinai Beth Israel, associate director, Cancer Clinical Trials Office, Mount Sinai Hospital, Mt. Sinai School of Medicine, discusses new data on immunotherapy for lung cancer.

Levy says the field of immunotherapy in lung cancer is very exciting. The unique ability to harness a patients’ immune system to attack the cancer is what sets these agents apart from other agents. There are currently multiple immunotherapeutic agents being looked at for the treatment of lung cancer, Levy says.

Results of the CheckMate 063 study, which evaluated the efficacy of nivolumab, showed that nivolumab delivered durable responses in patients with advanced squamous cell lung cancer.

Levy says approximately 15% of patients treated with nivolumab in this study responded — historical response rates in this setting are approximately 5-10%. Nivolumab also demonstrated a one-year overall survival rate of 40% in this trial. Levy says this is unprecedented, as historical rates are approximately 10-15%.

More resources are needed to find biomarkers to determine which patients will respond to each immunotherapy.

<<< View more from the 2014 Annual Lung Cancer Symposium


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 18th Annual International Lung Cancer Congress®Oct 31, 20181.5
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Publication Bottom Border
Border Publication
x